Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

Purpose: Conventional chemotherapy and targeted therapy are limited by systemic toxicity, poor tumor targeting, and multidrug resistance (MDR). Nanoparticle-based drug delivery offers improved pharmacokinetics, biocompatibility, enhanced permeability and retention (EPR), precise targeting, and potential to overcome resistance mechanisms such as efflux transporters, defective apoptosis, and hypoxia.

Hypothesis: No formal experimental hypothesis. Central thesis: nanoparticle-based delivery systems—including organic, inorganic, and hybrid nanoparticles—can improve cancer therapy by enhancing drug stability, tumor targeting, and combination delivery, and by reversing key mechanisms of drug resistance.

Aims: Discuss the roles of nanoparticles and hybrid nanoparticles for drug delivery in chemotherapy, targeted therapy, and immunotherapy. - Describe targeting mechanisms of nanoparticle-based drug delivery, including passive and active targeting. - Review nanoparticle functions in overcoming cancer drug resistance. - Summarize mechanisms of MDR, including efflux transporters, defective apoptotic pathways, and hypoxia. - Highlight the emerging role of nanoparticles in cancer immunotherapy.

Delivery system: Organic NPs: liposomes, polymeric NPs (PLGA, poly(lactic-co-glycolic acid)), dendrimers, polymeric micelles. - Inorganic NPs: gold NPs, carbon nanotubes, mesoporous silica NPs, magnetic NPs, quantum dots. - Hybrid NPs: lipid-polymer hybrid NPs, organic-inorganic hybrid NPs (liposome-silica, chitosan-carbon nanotube), cell membrane-coated NPs (leukocyte, red blood cell, platelet, cancer cell, bacterial, dual-membrane). - Targeting ligands: transferrin, folate, glycoproteins/lectins, EGFR, HER2, VEGF/VEGFR, αvβ3 integrin, VCAM-1, MMP-sensitive peptides. - Payloads: chemotherapeutics (doxorubicin, paclitaxel, docetaxel, gemcitabine), siRNA/miRNA (Bcl-2, P-gp, HIF-1α, miRNA-495), genes (p53, Bcl-2 convertor), efflux pump inhibitors, COX-2 inhibitors, NF-κB inhibitors, ceramide, resveratrol, cytokines (GM-CSF), monoclonal antibodies. - Targeting mechanisms: passive EPR effect, pH-sensitive release, active ligand-receptor targeting, tumor endothelium targeting, multistage size-changing NPs.

Approach: Narrative review of preclinical and clinical literature. Covers chemotherapy, targeted therapy, radiotherapy, hyperthermia, gene therapy, and immunotherapy. Discusses in vitro and in vivo cancer models, including breast, ovarian, prostate, lung, liver, pancreatic, bladder, and melanoma cancers. Clinical examples include PEGylated liposomal doxorubicin (Doxil), albumin-bound paclitaxel (Abraxane), and a phase I targeted nanoparticle siRNA trial in solid cancers (2010).

Key methods: Review-level synthesis of: - Nanoparticle characterization: size, shape, surface properties, PEGylation, biodistribution. - Targeting evaluation: EPR effect, ligand-receptor interactions, receptor-mediated endocytosis. - Drug resistance reversal: P-gp efflux inhibition, apoptosis induction, hypoxia targeting. - Immunotherapy: antigen delivery to APCs, artificial APCs, TME modulation, chemo-immunotherapy. - Clinical outcomes: cardiotoxicity, tolerated doses, tumor treatment efficacy, MDR reversal.

Key results: NPs with diameters of 10–100 nm are generally suitable for cancer therapy; <10 nm are cleared by kidneys, >100 nm are cleared by phagocytes. - PEGylation reduces opsonization and immune clearance, prolonging circulation. - Doxorubicin-loaded PEGylated liposomes reduced cardiotoxicity versus free doxorubicin. - Albumin-bound paclitaxel showed fewer side effects and allowed higher tolerated doses than solvent-based taxanes. - Actively targeted polymeric docetaxel nanoparticles showed more favorable tumor treatment efficacy than solvent-based docetaxel. - Co-delivery of COX-2 inhibitor and doxorubicin by NPs reversed MDR in breast cancer cells. - miRNA-495 plus doxorubicin in cancer cell membrane-coated silica NPs downregulated P-gp in multidrug-resistant lung cancer cells. - Paclitaxel plus Bcl-2 convertor gene in cationic NPs impaired P-gp-induced efflux and activated apoptosis in drug-resistant liver cancer. - Resveratrol plus docetaxel NPs downregulated anti-apoptotic genes and inhibited ABC transporters in multidrug-resistant prostate cancer. - Mitochondria-targeted paclitaxel TPP-Pluronic F127-hyaluronic acid nanomicelles caused mitochondrial outer membrane permeabilization, cytochrome C release, caspase-3/9 activation, and apoptosis in drug-resistant lung cancer cells. - HSP90 inhibitor 17AAG-loaded NPs improved bladder cancer treatment. - Nutlin-3a plus GM-CSF in spermine-modified acetalated dextran NPs improved CD8+ T cell proliferation and immune response. - Porous silicon NPs co-delivering chemotherapeutics and monoclonal antibodies stimulated complement activation and antibody-dependent cell cytotoxicity (ADCC). - A multistage NP system used 100-nm gelatin NPs degraded by tumor proteases to release 10-nm quantum dots for deep tumor penetration.

Interpretation: Nanoparticle-based drug delivery has entered a new era of cancer treatment. Organic, inorganic, and hybrid NPs improve pharmacokinetics, biocompatibility, tumor targeting, and stability while reducing systemic toxicity and overcoming drug resistance. Combination therapy using NPs loaded with targeting agents and cytotoxic drugs can reverse MDR. Hybrid NPs and immunotherapy-focused NPs are promising future directions, but clinical efficacy and safety require further investigation.

Limitations: Review article; no primary data. - Passive targeting limitations: non-specific drug distribution, non-universal EPR effect, variable tumor vessel permeability. - Inorganic NPs often have poorer biocompatibility and biodegradability. - Clinical translation of nanomedicines remains limited by pharmaceutical, biological, and translational barriers. - Nanovaccines and artificial APCs show increased efficacy preclinically but clinical efficacy remains unsatisfactory; safety and tolerance need further study. - Need better understanding of tumor microenvironment and nanoparticle-immune system crosstalk. - Optimal drug/gene combination regimens for MDR reversal are not yet established. - Further studies on individual cancer biological characteristics are needed for precise NP design.